ArticleBreast cancer research : BCR2004
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.
Article in Breast cancer research : BCR, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 77 citations in OpenAlex.
- A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.Journal of cancer research and clinical oncology · 2008Trial
- Bioactivity-Guided Fractionation of the Bidah Pomegranate Landrace Identifies a Bioactive Fraction Inducing Mitochondria-Associated Apoptotic Responses in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Identification of chemoresistance associated key genes-miRNAs-TFs in docetaxel resistant breast cancer by bioinformatics analysis.3 Biotech · 2024Article
- Alteration in the expression of the chemotherapy resistance‑related genes in response to chronic and acute hypoxia in pancreatic cancer.Biomedical reports · 2023Article
- The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Frontiers in pharmacology · 2023Review
- Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine.International journal of molecular sciences · 2022Article
- Article
- Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.Cell death discovery · 2021Article
- Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.Pharmaceutics · 2021Review
- EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.Iranian biomedical journal · 2020Article
- Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.Cancer chemotherapy and pharmacology · 2019Review
- Complex Epigenetic Regulation of Chemotherapy Resistance and Biohlogy in Esophageal Squamous Cell Carcinoma via MicroRNAs.International journal of molecular sciences · 2018Article
- Identification of zinc finger protein of the cerebellum 5 as a survival factor of prostate and colorectal cancer cells.Cancer science · 2017Article
- MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.Scientific reports · 2015Article
- Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin.BMC complementary and alternative medicine · 2015Article
- Role of miR-155 in drug resistance of breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells.International journal of nanomedicine · 2015Article
- Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.International journal of cancer · 2013Article
- ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection.Medical oncology (Northwood, London, England) · 2012Article
- The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939.Molecular biology reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
introductionDocetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of this resistance remain unclear. However, apoptosis and cell cycle regulation are key mechanisms by which most chemotherapeutic agents exert their cytotoxic effects.
methodsWe created two docetaxel-resistant human breast cancer cell lines (MCF-7 and MDA-MB-231) and performed cDNA microarray analysis to identify candidate genes associated with docetaxel resistance. Gene expression changes were validated at the RNA and protein levels by reverse transcription PCR and western analysis, respectively.
resultsGene expression cDNA microarray analysis demonstrated reduced p27 expression in docetaxel-resistant breast cancer cells. Although p27 mRNA expression was found to be reduced only in MCF-7 docetaxel-resistant sublines (2.47-fold), reduced expression of p27 protein was noted in both MCF-7 and MDA-MB-231 docetaxel-resistant breast cancer cells (2.83-fold and 3.80-fold, respectively).
conclusionsThis study demonstrates that reduced expression of p27 is associated with acquired resistance to docetaxel in breast cancer cells. An understanding of the genes that are involved in resistance to chemotherapy may allow further development in modulating drug resistance, and may permit selection of those patients who are most likely to benefit from such therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.